Portal de Periódicos da CAPES

SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study

2014; Elsevier BV; Volume: 25; Issue: 5 Linguagem: Inglês

10.1093/annonc/mdu084

1569-8041

M. Sinn, B.V. Sinn, Jana K. Striefler, Judith Lindner, Jens Stieler, Philipp Lohneis, Sven Bischoff, H. Bläker, Uwe Pelzer, Marcus Bahra, Manfred Dietel, Bernd Dörken, Helmut Oettle, Hanno Riess, Carsten Denkert,

Parathyroid Disorders and Treatments

Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral stroma but not for cytoplasmic SPARC expression. The aim of this study was to evaluate the impact of SPARC expression in pancreatic cancer patients treated with gemcitabine compared with untreated patients.CONKO-001 was a prospective randomized phase III study investigating the role of adjuvant gemcitabine when compared with observation. Tissue samples of 160 patients were available for SPARC immunohistochemistry on tissue microarrays to evaluate its impact on patient outcome.Strong stromal SPARC expression was associated with worse disease-free survival (DFS) and overall survival (OS) in the overall study population (DFS: P = 0.005, OS: P = 0.033). Its negative prognostic impact was restricted to patients treated with gemcitabine (DFS: P = 0.007, OS: P = 0.006). High cytoplasmic SPARC expression also was associated with worse patient outcome (DFS: P = 0.041, OS: P = 0.011). Again the effect was restricted to patients treated with gemcitabine (DFS: P = 0.002, OS: P = 0.003). In multivariable analysis, SPARC expression was independently predictive of patient outcome.Our data confirm the prognostic significance of SPARC expression after curatively intended resection. The negative prognostic impact was restricted to patients who received adjuvant treatment with gemcitabine, suggesting SPARC as a predictive marker for response to gemcitabine.